Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
News
Recent Posts
- Knowing my body isn’t my enemy helps me be at peace with ALS symptoms
- Study finds 4-month diagnostic gap between key ALS types
- Guest Voice: The collateral damage of ALS
- Developer to seek approval in Canada for ALS treatment aiding survival
- House passes bill to renew federal law for ALS research and care